

From: [REDACTED] [REDACTED]
Sent: 24 August 2009 09:56
To: TA Comm B
Subject: FW: Myelodysplastic syndromes - azacitidine_ACD
Attachments: Myelodysplastic syndromes - azacitidine_evaluation
report.pdf; Proforma for comments on executable model.doc;
Myelodysplastic syndromes - azacitidine_ACD.pdf

Nurses working in this area of health have reviewed the Appraisal Consultation document of technology appraisal for Myelodysplastic syndromes - azacitidine.

There are no further comments to submit at this stage on behalf of the Royal College of Nursing.

Thank you for the opportunity to review this document. We look forward to participating in the next stage of the appraisal.

Kind Regards,

[REDACTED]

Sent on behalf of

[REDACTED]

20 Cavendish Square
London
W1G 0RN
Tel: [REDACTED]
Fax: [REDACTED]